LGALS3 and type 2 diabetes mellitus: Since our study lacked disease-specific control groups, such as patients with T2DM alone or COVID-19 alone, we cannot determine whether the observed elevations in galectin-3 and sICAM-1 are specific to the combination of these two conditions or primarily driven by one of them.